The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2026 | The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into the use of intensive chemotherapy plus venetoclax in newly diagnosed acute myeloid leukemia (AML), highlighting the high complete remission rates achieved in clinical trials. This interview took place at the 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, there hasn’t been a vast amount of prospective data concerning the use of intensive chemotherapy plus venetoclax in newly diagnosed AML patients. There’s really three large American efforts to date with regard to this, one at MD Anderson, one at Albert Einstein, one at my place at Boston. Each one shows a very high complete remission rate with almost all the patients who achieve complete remission, doing so at a deep level of remission, so-called MRD negative remission...
Well, there hasn’t been a vast amount of prospective data concerning the use of intensive chemotherapy plus venetoclax in newly diagnosed AML patients. There’s really three large American efforts to date with regard to this, one at MD Anderson, one at Albert Einstein, one at my place at Boston. Each one shows a very high complete remission rate with almost all the patients who achieve complete remission, doing so at a deep level of remission, so-called MRD negative remission. And as far as they have safety, it seems to be safe. It’s a little bit more myelo-intensive than 3 plus 7 alone, as you might expect. In each case, the dose of venetoclax is limited to approximately 8 days, given approximately at the same time as the chemotherapy. In that fashion, we seem to see a relatively tolerable rate of grade 4 and grade 5 events. Well, we don’t have a great deal of data on that due to the paucity of data with regard to each individual genetic subtype of AML. However, it seems that those who have a reasonable amount of chemo-responsiveness, which means almost everybody except for people with p53 mutations or other truly adverse issues like complex karyotype often associated with P53 mutations or inversion 3 in the other relatively or highly chemo-responsive patients, it seems to be quite useful.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
